Should the knowledge needed to make the Covid-19 vaccines be freely available to all?
About this episode
In May, the Biden administration surprised the world by saying it would not object on an intellectual property waiver for Covid-19 vaccines.
America has been a staunch defender of patent protections, which bar new inventions being cheaply copied around the world. So, the first reactions to the announcement were - amazement, really. Second reactions tended to depend on which side of this debate you were on.
Who should be the gatekeepers of the knowledge which underpins the development of cutting edge pharmaceutical breakthroughs, like Covid-19 vaccines? In this week’s Inquiry, Sandra Kanthal finds out why the answer to that question really depends on who you ask.
Producer: Sandra Kanthal Editor: Richard Vadon
(Logos of various companies producing the Covid-19 vaccine. Credit: Artur Widak/Getty Images)
Get every episode summarized
Each time The Inquiry publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from The Inquiry
Can China’s polar silk road change global trade?
The Inquiry
Can Africa take control of its digital future?
The Inquiry
Should rivers have personhood?
The Inquiry
How has the Cockroach Janta Party changed India’s politics?
The Inquiry